Test Price
450 AED✅ Home Collection Available
MUM1 Immunohistochemistry (IHC) Test in UAE | 450 AED | 2026 DHA Guidelines
تحليل التعبير المناعي الكيميائي النسيجي لبروتين MUM1 في الإمارات | 450 درهم | وفق إرشادات هيئة الصحة بدبي 2026
ISO 9001:2015 Certified
Cert: INT/EGQ/2509DA/3139
Facility License: 9834453
Clinical Executive Summary
Accuracy Guarantee
99.9% Diagnostic Sensitivity via ISO 15189-Accredited IHC Processing with automated MUM1/IRF4 monoclonal antibody staining protocols.
Premium Logistics
Hospital-Grade FFPE Block Transport with ISO-Certified Cold-Chain Logistics & VIP Mobile Phlebotomy for ancillary blood panels (8 AM – 11 PM).
Clinical Guidance
Telephonic Post-Test Clinical Correlation Discussion with DHA-Licensed Pathologist — interpretation aligned with WHO 2026 Haematolymphoid Classification.
Insurance & Billing
Direct Billing Verification via WhatsApp: +971 54 548 8731
يُقدَّم هذا التحليل النسيجي المناعي المتقدم وفق أعلى معايير الجودة المعتمدة من هيئة الصحة بدبي، لضمان دقة تشخيصية فائقة لمرضى الأورام اللمفاوية وأورام الخلايا البلازمية في دولة الإمارات العربية المتحدة.
Clinical Overview: MUM1/IRF4 Immunohistochemistry
The MUM1 (Multiple Myeloma Oncogene 1 / IRF4) Immunohistochemistry Test is a high-specificity tissue-based biomarker assay that detects IRF4 protein expression in formalin-fixed paraffin-embedded (FFPE) biopsy sections. This test serves as a critical differentiating tool for B-cell lymphoma subtyping and plasma cell neoplasm confirmation. يُستخدم تحليل MUM1 الكيميائي النسيجي المناعي كأداة تشخيصية تفريقية أساسية في تصنيف الأورام اللمفاوية وتأكيد أورام الخلايا البلازمية.
| Parameter | Our MUM1 IHC Test (DHA Facility) | Standard Hospital IHC Panel |
|---|---|---|
| Precision / Antibody Specificity | MUM1/IRF4 Monoclonal Antibody (Clone MUM1p) — validated per CAP/ASH 2026 guidelines | Often generic B-cell panel without MUM1-specific subtyping resolution |
| Detection Method | Automated IHC Staining Platform with DAB Chromogen & LC-MS/MS Correlation Capability | Manual or semi-automated IHC with limited molecular correlation |
| Turnaround Time (TAT) | FFPE Block: 5 Days | Tissue Biopsy: 5 Days | Complex Resections: 7 Days | Typically 10–14 Days for comprehensive IHC reporting |
| Price Transparency | 450 AED — all-inclusive | Variable; often 600–900 AED with add-on charges |
Physician Insight & Safety Protocol
Dr. PRABHAKAR REDDY
Consultant Pathologist · DHA License: 61713011
"The MUM1 IHC stain is a cornerstone in modern haematopathology — but it must never be interpreted in isolation. A positive MUM1 result gains its true clinical meaning only when correlated with the full histomorphological picture, complementary markers (CD20, CD138, BCL6, Ki-67), and the patient's complete clinical history. I strongly advise all patients and referring physicians to discuss these results within a multidisciplinary tumour board context before making any therapeutic decisions."
⚠ Important Clinical Notice
Do not discontinue any prescribed medication or alter your treatment regimen based on MUM1 IHC results without consulting your treating oncologist or haematologist. This biomarker test is one component of a comprehensive diagnostic workup and does not independently dictate therapeutic changes.
Exclusion Criteria & Emergency Red Flags
Specimen Rejection Criteria
- Inadequately fixed tissue (fixation time less than 6 hours in 10% neutral buffered formalin)
- Crushed, cauterized, or necrotic biopsy specimens with less than 10% viable tumour cellularity
- Decalcified tissue processed with strong acids (may destroy MUM1 antigenicity)
- FFPE blocks older than 5 years without antigen retrieval validation
- Missing or incomplete surgical pathology report and clinical history
Patient Safety — Urgent Clinical Signs
- Rapidly enlarging lymph nodes with B-symptoms (fever, night sweats, >10% weight loss) — seek immediate oncology evaluation
- Unexplained hypercalcemia or renal impairment with suspected plasma cell dyscrasia
- Pathologic fractures or spinal cord compression symptoms in known or suspected myeloma
- Progressive neurological deficits in patients with known B-cell lymphoma
If you experience any of the above symptoms, seek emergency medical attention immediately. This test is a diagnostic aid; it does not replace urgent clinical assessment.
Pre-Test Submission Requirements
Submit tumour tissue in 10% neutral buffered formalin-saline OR a formalin-fixed paraffin-embedded (FFPE) block. Ship at room temperature in a sealed biohazard-compliant container.
Mandatory Documentation:
- A copy of the complete Histopathology Report (if prior biopsy performed)
- Exact anatomical site of biopsy
- Detailed clinical history including suspected diagnosis and relevant ICD-10 coding
- Referring physician's DHA license number and contact details
Sample acceptance daily until 6:00 PM GST. Reports issued within 5–7 days depending on specimen complexity.
UAE Regulatory & Legal Compliance
Federal Decree-Law No. 41 of 2024
Full compliance with Article 87 governing the handling, storage, and disposal of human tissue specimens. All FFPE blocks and residual tissue are managed per UAE biohazard and medical waste regulations.
CDS Law 2026 — Minors
For patients under 18 years of age, explicit parental or legal guardian consent is mandatory prior to tissue submission and IHC analysis, in strict accordance with UAE Child Data Sovereignty provisions.
UAE PDPL — Data Privacy
All patient-identifiable histopathology data, genomic correlates, and test results are encrypted and stored in full compliance with the UAE Personal Data Protection Law. No data sharing occurs without explicit patient consent.
Patient FAQ & Clinical Guidance
Q1: What does the MUM1 Immunohistochemistry test actually detect, and why has my oncologist ordered it?
Snippet Answer: The MUM1 IHC test detects IRF4 protein expression within tumour cells to differentiate between specific subtypes of B-cell lymphomas and plasma cell neoplasms with high precision. Your oncologist has likely ordered this test to distinguish diffuse large B-cell lymphoma (DLBCL) subtypes or to confirm a suspected plasma cell dyscrasia when standard histology alone is inconclusive. MUM1 positivity is particularly informative in classifying the activated B-cell (ABC) subtype of DLBCL, which carries distinct prognostic and therapeutic implications. The results guide targeted therapy selection and enrolment eligibility for clinical trials.
ما الذي يكشفه تحليل MUM1 الكيميائي النسيجي المناعي؟
يكتشف هذا التحليل تعبير بروتين IRF4 داخل الخلايا السرطانية للتمييز بين الأنواع الفرعية للأورام اللمفاوية ونيوبلازمات الخلايا البلازمية بدقة عالية. يطلبه طبيب الأورام لتحديد النوع الفرعي لورم اللمفاوية البائية كبير الخلايا المنتشر أو لتأكيد اضطراب الخلايا البلازمية المشتبه به.
Q2: How should I prepare for the MUM1 IHC tissue test, and is there any risk involved?
Snippet Answer: No patient preparation is required for the MUM1 IHC itself because the analysis is performed on previously collected biopsy tissue rather than on the patient directly. The biopsy procedure that obtained your tissue sample would have been performed earlier by your surgeon or interventional radiologist under their specific preparation guidelines. There is zero additional risk from the IHC staining process — it is a laboratory procedure conducted exclusively on the excised tissue block. However, you must ensure your referring physician has submitted the complete histopathology report and clinical history alongside the tissue specimen to enable accurate interpretation.
كيف أستعد لتحليل MUM1 النسيجي وهل هناك أي مخاطر؟
لا يتطلب تحليل MUM1 أي تحضير من المريض لأنه يُجرى على عينة النسيج المستأصلة مسبقاً وليس على المريض مباشرة. لا توجد أي مخاطر إضافية من عملية التلوين المناعي النسيجي لأنها إجراء مخبري بحت. يجب التأكد من تقديم التقرير النسيجي المرضي الكامل والتاريخ السريري مع العينة.
Q3: What does a positive MUM1 result mean for my diagnosis and treatment prognosis?
Snippet Answer: A positive MUM1 IHC result indicates that your tumour cells express the IRF4 transcription factor, which is characteristic of certain lymphoid malignancies including the activated B-cell subtype of DLBCL, primary mediastinal B-cell lymphoma, classical Hodgkin lymphoma, and plasma cell neoplasms like multiple myeloma. This finding helps your oncologist refine the pathological classification and may influence the choice of first-line chemotherapy or targeted biologic therapy. Importantly, MUM1 positivity alone does not determine your overall prognosis — its significance depends entirely on the complete immunophenotypic panel, molecular genetic findings, and your individual clinical parameters such as age, performance status, and disease stage.
ماذا تعني نتيجة MUM1 الإيجابية لتشخيصي ومآل علاجي؟
تشير نتيجة MUM1 الإيجابية إلى أن خلايا الورم تعبر عن عامل النسخ IRF4، وهو ما يميز أوراماً لمفاوية معينة مثل النوع الفرعي للخلايا البائية المنشطة من ورم اللمفاوية كبير الخلايا المنتشر، وأورام الخلايا البلازمية. تساعد هذه النتيجة طبيب الأورام في تحسين التصنيف المرضي وقد تؤثر على اختيار العلاج الكيميائي الأولي أو العلاج البيولوجي الموجه. تعتمد الأهمية التنبؤية الكاملة على اللوحة المناعية الكاملة والنتائج الجينية الجزيئية والمعايير السريرية الفردية.
Direct Billing & Home Collection Support
Contact our DHA-licensed coordination team for insurance verification, VIP mobile phlebotomy scheduling, or clinical result inquiries.
+971 54 548 8731
WhatsApp · Available 8 AM – 11 PM GST · 7 Days
Facility License: 9834453 | ISO 9001:2015 Cert: INT/EGQ/2509DA/3139
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians